Cargando…
Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors
BACKGROUND: Numerous efficacious chemotherapy regimens may cause thrombocytopenia. Thrombopoietin receptor (TPO-R) agonists, such as eltrombopag, represent a novel approach for the treatment of chemotherapy-induced thrombocytopenia. The TPO-R MPL is expressed on megakaryocytes and megakaryocyte prec...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480928/ https://www.ncbi.nlm.nih.gov/pubmed/22967017 http://dx.doi.org/10.1186/1471-2407-12-405 |
_version_ | 1782247658783506432 |
---|---|
author | Erickson-Miller, Connie L Pillarisetti, Kodandaram Kirchner, Jennifer Figueroa, David J Ottesen, Lone Martin, Anne-Marie Liu, Yuan Kamel, Yasser Mostafa Messam, Conrad |
author_facet | Erickson-Miller, Connie L Pillarisetti, Kodandaram Kirchner, Jennifer Figueroa, David J Ottesen, Lone Martin, Anne-Marie Liu, Yuan Kamel, Yasser Mostafa Messam, Conrad |
author_sort | Erickson-Miller, Connie L |
collection | PubMed |
description | BACKGROUND: Numerous efficacious chemotherapy regimens may cause thrombocytopenia. Thrombopoietin receptor (TPO-R) agonists, such as eltrombopag, represent a novel approach for the treatment of chemotherapy-induced thrombocytopenia. The TPO-R MPL is expressed on megakaryocytes and megakaryocyte precursors, although little is known about its expression on other tissues. METHODS: Breast, lung, and ovarian tumor samples were analyzed for MPL expression by microarray and/or quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and for TPO-R protein expression by immunohistochemistry (IHC). Cell line proliferation assays were used to analyze the in vitro effect of eltrombopag on breast, lung, and ovarian tumor cell proliferation. The lung carcinoma cell lines were also analyzed for TPO-R protein expression by Western blot. RESULTS: MPL mRNA was not detectable in 118 breast tumors and was detectable at only very low levels in 48% of 29 lung tumors studied by microarray analysis. By qRT-PCR, low but detectable levels of MPL mRNA were detectable in some normal (14-43%) and malignant (3-17%) breast, lung, and ovarian tissues. A comparison of MPL to EPOR, ERBB2, and IGF1R mRNA demonstrates that MPL mRNA levels were far lower than those of EPOR and ERBB2 mRNA in the same tissues. IHC analysis showed negligible TPO-R protein expression in tumor tissues, confirming mRNA analysis. Culture of breast, lung, and ovarian carcinoma cell lines showed no increase, and in fact, showed a decrease in proliferation following incubation with eltrombopag. Western blot analyses revealed no detectable TPO-R protein expression in the lung carcinoma cell lines. CONCLUSIONS: Multiple analyses of breast, lung, and ovarian tumor samples and/or cell lines show no evidence of MPL mRNA or TPO-R protein expression. Eltrombopag does not stimulate growth of breast, lung, or ovarian tumor cell lines at doses likely to exert their actions on megakaryocytes and megakaryocyte precursors. |
format | Online Article Text |
id | pubmed-3480928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34809282012-10-27 Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors Erickson-Miller, Connie L Pillarisetti, Kodandaram Kirchner, Jennifer Figueroa, David J Ottesen, Lone Martin, Anne-Marie Liu, Yuan Kamel, Yasser Mostafa Messam, Conrad BMC Cancer Research Article BACKGROUND: Numerous efficacious chemotherapy regimens may cause thrombocytopenia. Thrombopoietin receptor (TPO-R) agonists, such as eltrombopag, represent a novel approach for the treatment of chemotherapy-induced thrombocytopenia. The TPO-R MPL is expressed on megakaryocytes and megakaryocyte precursors, although little is known about its expression on other tissues. METHODS: Breast, lung, and ovarian tumor samples were analyzed for MPL expression by microarray and/or quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and for TPO-R protein expression by immunohistochemistry (IHC). Cell line proliferation assays were used to analyze the in vitro effect of eltrombopag on breast, lung, and ovarian tumor cell proliferation. The lung carcinoma cell lines were also analyzed for TPO-R protein expression by Western blot. RESULTS: MPL mRNA was not detectable in 118 breast tumors and was detectable at only very low levels in 48% of 29 lung tumors studied by microarray analysis. By qRT-PCR, low but detectable levels of MPL mRNA were detectable in some normal (14-43%) and malignant (3-17%) breast, lung, and ovarian tissues. A comparison of MPL to EPOR, ERBB2, and IGF1R mRNA demonstrates that MPL mRNA levels were far lower than those of EPOR and ERBB2 mRNA in the same tissues. IHC analysis showed negligible TPO-R protein expression in tumor tissues, confirming mRNA analysis. Culture of breast, lung, and ovarian carcinoma cell lines showed no increase, and in fact, showed a decrease in proliferation following incubation with eltrombopag. Western blot analyses revealed no detectable TPO-R protein expression in the lung carcinoma cell lines. CONCLUSIONS: Multiple analyses of breast, lung, and ovarian tumor samples and/or cell lines show no evidence of MPL mRNA or TPO-R protein expression. Eltrombopag does not stimulate growth of breast, lung, or ovarian tumor cell lines at doses likely to exert their actions on megakaryocytes and megakaryocyte precursors. BioMed Central 2012-09-11 /pmc/articles/PMC3480928/ /pubmed/22967017 http://dx.doi.org/10.1186/1471-2407-12-405 Text en Copyright ©2012 Erickson-Miller et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Erickson-Miller, Connie L Pillarisetti, Kodandaram Kirchner, Jennifer Figueroa, David J Ottesen, Lone Martin, Anne-Marie Liu, Yuan Kamel, Yasser Mostafa Messam, Conrad Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors |
title | Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors |
title_full | Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors |
title_fullStr | Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors |
title_full_unstemmed | Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors |
title_short | Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors |
title_sort | low or undetectable tpo receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480928/ https://www.ncbi.nlm.nih.gov/pubmed/22967017 http://dx.doi.org/10.1186/1471-2407-12-405 |
work_keys_str_mv | AT ericksonmillerconniel loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors AT pillarisettikodandaram loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors AT kirchnerjennifer loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors AT figueroadavidj loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors AT ottesenlone loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors AT martinannemarie loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors AT liuyuan loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors AT kamelyassermostafa loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors AT messamconrad loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors |